Ligand Pharmaceuticals Incorporated (LGND)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 830,439 | 700,913 | 597,485 | 821,629 | 709,525 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $830,439K
= 0.00
The debt-to-equity ratio for Ligand Pharmaceuticals Incorporated has consistently been 0.00 from December 31, 2020, to December 31, 2024. This indicates that the company has not utilized any debt to finance its operations during this period, and its operations have been primarily funded by equity. A debt-to-equity ratio of 0.00 suggests a low financial risk, as the company is not reliant on borrowed funds, and shareholders have a higher ownership stake in the company's assets. However, it is important to note that a very low or zero debt-to-equity ratio may also indicate underutilization of debt financing opportunities that could potentially enhance the company's growth and profitability in the long term.
Peer comparison
Dec 31, 2024